Janux Therapeutics, Inc. (JANX)

Market Cap	940.46M -41.0%
Revenue (ttm)	10.00M -5.6%
Net Income	-113.63M
EPS	-1.83
Shares Out	60.83M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,965,809
Open	15.80
Previous Close	15.87
Day's Range	15.32 - 15.94
52-Week Range	12.12 - 35.34
Beta	2.81
Analysts	Buy
Price Target	48.73 (+215.2%)
Earnings Date	May 7, 2026

About JANX

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company’s clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 11, 2021
• Employees: 109
• Stock Exchange: NASDAQ
• Ticker Symbol: JANX
• Website: https://www.januxrx.com

Financial Performance

In 2025, Janux Therapeutics's revenue was $10.00 million, a decrease of -5.55% compared to the previous year's $10.59 million. Losses were -$113.63 million, 64.7% more than in 2024.

Analyst Summary

According to 12 analysts, the average rating for JANX stock is "Buy." The 12-month stock price target is $48.73, which is an increase of 215.20% from the latest price.

Price Target

$48.73

(215.20% upside)

Analyst Consensus: Buy